Allogeneic HPyV-2-specific T-cell Therapy (Hannover Medical School)

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameAllogeneic HPyV-2-specific T-cell Therapy (Hannover Medical School)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsPosterior Leukoencephalopathy Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesHannover Medical School

China Registration ClassN/A

Develop Information

Active CompaniesHannover Medical School

Inactive CompaniesN/A

Active IndicationsPosterior Leukoencephalopathy Syndrome

Inactive IndicationsN/A

Other Information

ATC CodeN/A